Keyword Search
2015 | 2014 | 2013 | 2012 | 2011
08/11/15Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026
ALISO VIEJO, Calif., Aug. 11, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that a panel of the U.S. Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA (U.S. Patent Nos. 7,659,282 (the '282' patent) and 8,227,484 (the '484' patent)). The decision confirms patent protection for NUEDEXTA until 2026 in the United States. The Appeals Court ruling affirmed the April 2014 decision upholding the '282' and '48... 
 Printer Friendly Version
07/23/15Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference
--New Data Demonstrate Treatment Effects on Pseudobulbar Affect (PBA) with NUEDEXTA Regardless of Concomitant Antidepressant Use-- ALISO VIEJO, Calif., July 23, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced new findings from the dementia/Alzheimer's disease cohort of the PRISM II study, a phase IV study evaluating the safety and effectiveness of NUEDEXTA® in treating pseudobulbar affect (PBA) in patients with dementia/Alzheimer's disease, stroke and traumatic brain injur... 
 Printer Friendly Version
06/30/15Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study
-- Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in PBA Patients Who Had an Underlying Stroke or Traumatic Brain Injury -- ALISO VIEJO, Calif. , June 30, 2015 /PRNewswire/ --  Avanir Pharmaceuticals, Inc. today announced top-line data from the PRISM II study showing that treatment with NUEDEXTA® was associated with a statistically significant reduction in symptoms of pseudobulbar affect (PBA) in pat... 
 Printer Friendly Version
06/17/15Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825 Head-to-Head COMPASS Study in the Journal "Headache"
--COMPASS Trial Demonstrated Greater Rates of Migraine Headache Reduction in as Early as 15 Minutes with AVP-825 Treatment Compared to Well-established Standard of Care, Oral Sumatriptan Treatment-- --Additional Data Related to AVP-825 for the Acute Treatment of Migraine to be Presented at the American Headache Society Annual Meeting-- ALISO VIEJO, Calif., June 17, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that COMPASS, its Phase IIIb, cross-over clinical trial co... 
 Printer Friendly Version
05/05/15Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms in Retired Professional Football Players at the 12th Annual North American Brain Injury Society Conference
-- Ninety nine percent of respondents experienced some form of brain trauma during their playing career and one third also report symptoms of PBA -- ALISO VIEJO, Calif., May 5, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced the presentation of survey results assessing the prevalence and impact of pseudobulbar affect (PBA) symptoms in former professional football players.  The survey showed that nearly all players had experienced head trauma or injury during their football... 
 Printer Friendly Version
05/01/15Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition
--Avanir Pharmaceuticals Takes Unique Approach to Patient Education in New Initiative-- ALISO VIEJO, Calif., May 1, 2015 /PRNewswire/ -- Legendary actor and director Danny Glover joins Avanir Pharmaceuticals, Inc. in a new PBAFacts campaign designed to educate and encourage patients with neurologic conditions, and their caregivers, to learn more about Pseudobulbar Affect (PBA) and to speak with their physician. The campaign hinges on the idea that an actor has the ability to cry and laugh o... 
 Printer Friendly Version
04/15/15Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the American Academy of Neurology (AAN) 2015 Annual Meeting
ALISO VIEJO, Calif., April 15, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from the Phase 2 study of AVP-923 for the treatment of agitation in Alzheimer's disease, data from the Alzheimer's cohort of PRISM II of NUEDEXTA® for the treatment of Pseudobulbar Affect (PBA) and several data presentations on the use of AVP-825 for the treatment of acute migraine, will be presented at the... 
 Printer Friendly Version
01/21/15Football Hall-of-Famer Barry Sanders Tackles Pseudobulbar Affect; A Little-known But Widespread Condition Caused by Brain Injury
'Tackle PBA,' a New Educational Campaign, Addresses Why Many Former Pro Football Players Cry or Laugh Uncontrollably with Little to No Clear Trigger ALISO VIEJO, Calif., January 21, 2015 /PRNewswire/ -- New research shows 99 percent of former professional football players surveyed by the Gridiron Greats Assistance Fund, Inc., have suffered a head injury, repeated concussions, or a blow to the head sometime during their football career. More concerning is that a third of these players admi... 
 Printer Friendly Version